These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 11410411

  • 1. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.
    Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2001 May; 86(5):485-93. PubMed ID: 11410411
    [Abstract] [Full Text] [Related]

  • 2. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 3. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K.
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [Abstract] [Full Text] [Related]

  • 4. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW, Kolesar JM.
    Clin Ther; 2009 Nov; 31 Pt 2():2290-311. PubMed ID: 20110042
    [Abstract] [Full Text] [Related]

  • 5. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
    Roué G, López-Guerra M, Milpied P, Pérez-Galán P, Villamor N, Montserrat E, Campo E, Colomer D.
    Clin Cancer Res; 2008 Nov 01; 14(21):6907-15. PubMed ID: 18980985
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
    Szmigielska-Kaplon A, Smolewski P, Najder M, Robak T.
    Ann Hematol; 2002 Sep 01; 81(9):508-13. PubMed ID: 12373351
    [Abstract] [Full Text] [Related]

  • 7. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia.
    Schwänen C, Hecker T, Hübinger G, Wölfle M, Rittgen W, Bergmann L, Karakas T.
    Leukemia; 2002 Oct 01; 16(10):2096-105. PubMed ID: 12357363
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bendamustine: a new look at an old drug.
    Kalaycio M.
    Cancer; 2009 Feb 01; 115(3):473-9. PubMed ID: 19117340
    [Abstract] [Full Text] [Related]

  • 11. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
    Sanchez-Gonzalez B, Peñalver FJ, Medina A, Guillén H, Calleja M, Gironella M, Arranz R, Sebastian E, de Oña R, Cánovas A, de la Fuente I, Grande C, Sancho JM, Perez R, Domingo E, Lopez-Lorenzo JL, Prieto E, Panizo C, Gorosquieta A, Perez I, Cervera JM, Marin M, Mencha C, Ramila E, Salar A.
    Leuk Res; 2012 Jun 01; 36(6):709-14. PubMed ID: 22154023
    [Abstract] [Full Text] [Related]

  • 12. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Ujjani C, Cheson BD.
    Expert Rev Anticancer Ther; 2010 Sep 01; 10(9):1353-65. PubMed ID: 20836669
    [Abstract] [Full Text] [Related]

  • 13. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
    Rummel MJ.
    Semin Hematol; 2008 Jul 01; 45(3 Suppl 2):S7-10. PubMed ID: 18760709
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bendamustine: new perspective for an old drug in lymphoproliferative disorders.
    Montillo M, Ricci F, Tedeschi A, Vismara E, Morra E.
    Expert Rev Hematol; 2010 Apr 01; 3(2):131-48. PubMed ID: 21083456
    [Abstract] [Full Text] [Related]

  • 16. Bendamustine: rebirth of an old drug.
    Cheson BD, Rummel MJ.
    J Clin Oncol; 2009 Mar 20; 27(9):1492-501. PubMed ID: 19224851
    [Abstract] [Full Text] [Related]

  • 17. Bendamustine in the treatment of chronic lymphocytic leukemia.
    Knauf W.
    Expert Rev Anticancer Ther; 2009 Feb 20; 9(2):165-74. PubMed ID: 19192955
    [Abstract] [Full Text] [Related]

  • 18. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines.
    Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, Berger MR.
    J Cancer Res Clin Oncol; 2002 May 20; 128(5):271-8. PubMed ID: 12029443
    [Abstract] [Full Text] [Related]

  • 19. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS.
    J Clin Oncol; 2005 May 20; 23(15):3383-9. PubMed ID: 15908650
    [Abstract] [Full Text] [Related]

  • 20. Bendamustine's emerging role in the management of lymphoid malignancies.
    Rummel MJ, Gregory SA.
    Semin Hematol; 2011 Apr 20; 48 Suppl 1():S24-36. PubMed ID: 21530769
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.